Search

Your search keyword '"Yutiq (Medication)"' showing total 139 results
Start Over Descriptor "Yutiq (Medication)" Topic business
139 results on '"Yutiq (Medication)"'

1. Q2 2024 ANI Pharmaceuticals Inc Earnings Call - Final

Subjects
ANI Pharmaceuticals Inc., Pharmaceutical industry, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good day, everyone, and welcome to today's ANI Pharmaceuticals, Inc. second quarter 2024 earnings results call. Please note this call is being recorded. (Operator Instructions) It is now [...]

Published
2024

2. ANI Pharmaceuticals Inc will Acquire Alimera Sciences Inc M&A Call - Final

Subjects
ANI Pharmaceuticals Inc. -- Mergers, acquisitions and divestments, Pharmaceutical industry -- Mergers, acquisitions and divestments, Company acquisition/merger, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the ANI Pharmaceuticals conference to discuss acquisition of Alimera Sciences. (Operator Instructions) Please note today's call will be recorded, and I'll be standing [...]

Published
2024

3. Q1 2024 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences first-quarter and 2024 financial results and corporate update conference call. (Operator Instructions) [...]

Published
2024

4. Alimera Sciences Reports Second Quarter 2024 Results

Subjects
ANI Pharmaceuticals Inc. -- Company sales and earnings, Pharmaceutical industry -- Company sales and earnings, Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

Net Revenue up 54% to $27 Million vs. Q2 2023 Global End User Demand up 6% vs. Q2 2023 Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, [...]

Published
2024

5. Q4 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences fourth quarter and fiscal year 2023 financial results and corporate update conference [...]

Published
2024

6. Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Business, Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Kevin, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the EyePoint Pharmaceuticals' fourth quarter and [...]

Published
2024

7. Alimera Sciences reports Q3 EPS (6c), consensus (6c)

Subjects
Company earnings/profit, Business, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

Reports Q3 revenue $23.4M, consensus $22.72M. 'We are pleased to announce record net revenue of $23.4 million, a significant decrease in our net loss and record Adjusted EBITDA in our [...]

Published
2023

8. Alimera Sciences expects top-lined data from NEW DAY study in 1Q25

Subjects
Medical research, Medicine, Experimental, Fluocinolone acetonide, Vascular endothelial growth factor, Fluocinolone, Business, News, opinion and commentary, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera's overenrolled NEW DAY Study evaluating ILUVIEN's utility as baseline therapy head-to-head versus the leading anti-VEGF in the treatment of diabetic macular edema has completed enrollment with 306 patients and [...]

Published
2023

9. ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences

Subjects
United States. Securities and Exchange Commission, ANI Pharmaceuticals Inc., Diseases -- United States, Pharmaceutical industry, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenue [...]

Published
2024

10. Alimera Sciences Reports First Quarter 2024 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May [...]

Published
2024

11. Q3 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences third-quarter 2022 (sic - 2023) financial results and corporate update conference call. [...]

Published
2023

13. Guggenheim likes Yutiq sale, ups EyePoint target to $55

Subjects
Business, News, opinion and commentary, Yutiq (Medication)
Abstract

Guggenheim analyst Yatin Suneja raised the firm's price target on EyePoint Pharmaceuticals (EYPT) to $55 from $52 and keeps a Buy rating on the shares after the company sold Yutiq [...]

Published
2023

14. EyePoint sells YUTIQ to Alimera Sciences for $82.5M cash plus royalties

Subjects
Royalties, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals entered into a definitive agreement for the sale of YUTIQ 0.18mg to Alimera Sciences. YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment of the [...]

Published
2023

15. Alimera Sciences acquires U.S. commercial rights to YUTIQ from EyePoint

Subjects
Business, News, opinion and commentary, Yutiq (Medication)
Abstract

Alimera Sciences (ALIM) announced its acquisition of additional commercialization rights for YUTIQ 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals [...]

Published
2023

16. Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE [...]

Published
2024

17. Alimera Completes Recruitment for the Synchronicity Study

Subjects
Fluocinolone acetonide, Fluocinolone, Industry hiring, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

ATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2024

18. Q2 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Second Quarter 2023 Financial Results Conference Call. (Operator Instructions) Participants of this [...]

Published
2023

19. Q1 2023 Alimera Sciences Inc Earnings Call - Final

Subjects
Public relations agencies, Investor relations, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Corporate Update Conference Call. (Operator Instructions) Participants of this call are advised [...]

Published
2023

20. Q1 2023 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Desean, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First [...]

Published
2023

21. Q1 2023 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Desean, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First [...]

Published
2023

23. Alimera Sciences Reports Third Quarter 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Net Revenue up 72% to $23.4 Million vs. Q3 2022 Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022 Adjusted EBITDA of $5.4 Million in Q3 2023 Successful [...]

Published
2023

24. Alimera Announces Multiple Presentations Highlighting ILUVIEN(R) and YUTIQ(R) Data at Retina Society Annual Congress

Subjects
Medical research, Medicine, Experimental, Societies, Fluocinolone acetonide, Fluocinolone, Associations, institutions, etc., Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with [...]

Published
2023

25. Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Patient compliance, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good day, and welcome to the EyePoint Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is being [...]

Published
2023

26. Q3 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Chief operating officers, Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Welcome to the EyePoint Third Quarter 2022 Financial Results conference call. (Operator Instructions) As a reminder, today's conference call is being recorded. I will now turn the conference [...]

Published
2022

27. EyePoint announce approval of new drug application by China's NMPA for YUTIQ

Subjects
Drugs -- Vehicles, Drug approval, Drug delivery systems, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals and OcuMension Therapeutics announced that China's Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA, has approved YUTIQ 0.18mg for the treatment of chronic non-infectious [...]

Published
2022

28. Alimera Sciences Reports Second Quarter 2023 Results

Subjects
Company earnings/profit, Banking, finance and accounting industries, Business, Yutiq (Medication), Iluvien (Medication)
Abstract

Alimera Acquired U.S. Commercial Rights to YUTIQ [sup. (R) ] Landmark NEW DAY Study Completed Enrollment with over 300 Patients Consolidated Net Revenue of $17.5 Million Up 20% vs. Second [...]

Published
2023

30. EyePoint Pharmaceuticals Announces Chief Executive Officer Transition

Subjects
Eye diseases, Succession planning (Business), Chief operating officers, Chief executive officers, Medical colleges, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

- Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer - - Nancy S. Lurker Transitions to Executive Vice Chair of the Board [...]

Published
2023

31. Q2 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Michelle, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter [...]

Published
2022

32. Q2 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Michelle and I'll be your conference operator today. At this time I would like to welcome everyone to the EyePoint Pharmaceuticals Second Quarter [...]

Published
2022

33. EyePoint Pharmaceuticals Inc Investor Day - Final

Subjects
Business, Eylea (Medication), Yutiq (Medication)
Abstract

Presentation NANCY S. LURKER, PRESIDENT, CEO & DIRECTOR, EYEPOINT PHARMACEUTICALS, INC.: (technical difficulty) started. So I want to welcome everybody here. So if you could take your seats. We're going [...]

Published
2022

35. Alimera Acquires U.S. Commercial Rights to YUTIQ(R)

Subjects
Fluocinolone acetonide, Financial statements, Fluocinolone, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in [...]

Published
2023

37. Q1 2022 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Josh, and I'll be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals First Quarter [...]

Published
2022

38. EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) - Final

Subjects
Fluocinolone acetonide -- Conferences, meetings and seminars, Ophthalmology -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, Eylea (Medication), Yutiq (Medication)
Abstract

Presentation MAYANK MAMTANI, ANALYST, B. RILEY SECURITIES, INC.: Good morning. Welcome back, everyone, to day two of B. Riley Neuro and Ophthalmology Conference. We thank you all for being part [...]

Published
2022

40. EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ

Subjects
Eye diseases, Leases, Commercial buildings, Banking, finance and accounting industries, Business, Yutiq (Medication)
Abstract

- State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts - - Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 - [...]

Published
2023

41. EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines

Subjects
Patient compliance, Prospective payment systems (Medical care), Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication)
Abstract

- Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 - - Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for [...]

Published
2023

42. Q4 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
United States. Food and Drug Administration, Patient compliance, Business, Eylea (Medication), Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Jonathan, and I will be your conference operator today. At this time, I would like to welcome everyone to the EyePoint Pharmaceuticals Fourth [...]

Published
2022

43. Q3 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, American Academy of Ophthalmology, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good day, and thank you for standing by. Welcome to the EyePoint Third Quarter 2021 Financial Results Conference Call. (Operator Instructions) Please be advised that today's conference is [...]

Published
2021

46. Q2 2021 EyePoint Pharmaceuticals Inc Earnings Call - Final

Subjects
Business, Dexycu (Medication), Yutiq (Medication)
Abstract

Presentation OPERATOR: Good morning. My name is Norma, and I'll be your conference operator today. At this time, I would like to welcome everyone to EyePoint Pharmaceuticals' Second Quarter 2021 [...]

Published
2021

47. EyePoint sees Q3 revenue $5.5M-$5.9M, consensus $7.6M

Subjects
COVID-19, Company earnings/profit, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

'We were pleased to see the continued return of customer demand for both YUTIQ and DEXYCU during the third quarter of 2020, as more healthcare facilities re-opened for business and [...]

Published
2020

48. EyePoint presents data supporting YUTIQ at ASRS Annual Meeting

Subjects
Fluocinolone, Business, News, opinion and commentary, Yutiq (Medication)
Abstract

EyePoint Pharmaceuticals announced the presentation of data supporting YUTIQ 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye. The data were presented in two [...]

Published
2020

49. EyePoint sees no disruptionds to YUTIQ, DEXYCU supply chains

Subjects
Business logistics, Produce industry, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

There have been no disruptions to the supply chains for YUTIQ and DEXYCU and the Company continues to produce finished product for commercial [...]

Published
2020

50. EyePoint says YUTIQ, DEXYCU supply chains have not been interrupted

Subjects
Medical offices, Business logistics, Physicians, Raw materials, Business, News, opinion and commentary, Dexycu (Medication), Yutiq (Medication)
Abstract

The company said, 'EyePoint is committed to providing uninterrupted access to our products during the COVID-19 pandemic for those patients who are in essential need of treatment. Our supply chains [...]

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results